🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07267273
Recruiting Not applicable

Betamethasone Phonophoresis For Vitiligo

NCT07267273 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11-10
Last updated
2025-12-05

Condition(s) studied

Vitiligo

Investigational drug(s) / intervention(s)

Beclomethasone →

Beclomethasone: to determine the effect of betamethasone phonophoresis on vitiligo patients.

Study summary

Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin.

Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease.

Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients .

Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.

Eligibility

Sex
ALL
Min age
25 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Male and female patients diagnosed with vitiligo. * Medically and psychologically stable patients. * Good cognitive abilities to understand the requirements of the study. * All patients enrolled to the study will have their informed consent. * they had no contraindications to the use of therapeutic ultrasound Exclusion Criteria: * Pregnancy or lactation. * Immunosuppression. * Alcohol abuse. * History of spontaneous re-pigmentation of lesions. * Presence of skin characteristics that may interfere with study assessment. * Active bacterial/viral infection. * Patients on other immune suppressants and phototherapy * Patients currently participating in any other clinical study * Uncooperative patients.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Hospital Cairo Egypt Recruiting

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07267273 on ClinicalTrials.gov ↗ ← All trials in Egypt